Intravenous (IV) ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever, and inflammation occurred due to a disease, operative procedures or trauma, and acute illness. The intravenous (IV) route for ibuprofen administration has a faster onset of action as compared to the other routes. IV ibuprofen is preferred for the management of post-operative and acute pain. The demand for ibuprofen has increased due to the side effects of opioid analgesics such as respiratory depression, allergic reactions, sedation, and gastrointestinal events.
The market for IV ibuprofen for pain management is in its nascent stage. The world IV ibuprofen market was valued at $3.6 million in 2015, and is projected to reach $14.2 million by 2022, registering a CAGR of 20% during the forecast period. Advantages associated with IV ibuprofen such as rapid result and targeted drug delivery have resulted in the growth of this market. In 2015, FDA approved IV ibuprofen for pediatric use, due to which the market is expected to register a significant growth during the forecast period. Other factors that affect the market growth significantly include increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, trauma, and shifting trend towards the use of non-opioids drugs. Factors that would hamper the market growth include side effects associated with IV ibuprofen and lengthy approval process.
The world IV Ibuprofen market is segmented on the basis of indication, age group, and country. By indication, further sub-segments considered in this report include pain/inflammation and fever. The age groups considered are pediatrics and adults. The market is segmented into four countries namely Australia, Canada, South Korea, and the U.S.
Currently, Cumberland Pharmaceuticals Inc., is the only IV ibuprofen manufacturer in the market. The company has collaborated with the local/regional drug manufacturers to target new countries by getting product approvals. The key companies profiled in this report are Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc. (acquired by Teligent, Inc.), CSL Limited, Sandor Medicaids Pvt Ltd., PT. Soho Industri Pharmasi, Germin MED, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd., and Laboratorios Valmorca, C.A.
KEY BENEFITS FOR STAKEHOLDERS:
INTRAVENOUS (IV) IBUPROFEN MARKET KEY SEGMENTS:
By Age Group
SIMILAR MARKET STUDIES
Notes: Sales, means the sales volume of Nano Medical Device Revenue, means the sales value of Nano Medical Device This report studies sales (consumption) of Nano Medical Device in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share ...
February 2017 | $4000 | View Details >>
In this report, the United States Portable Ultrasound Equipment market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven ...
April 2017 | $3800 | View Details >>
The Global and Chinese Advanced Remote Patient Monitoring Systems Industry, 2011-2021 Market Research Report is a professional and in-depth study on the current state of the global Advanced Remote Patient Monitoring Systems industry with a focus on the Chinese market. The report provides key statistics on the market status of ...
January 2016 | $2800 | View Details >>
The Europe Bipolar Coagulation Electrosurgical Unit Industry 2016 Deep Market Research Report is a professional and in-depth study on the current state of the Bipolar Coagulation Electrosurgical Unit industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Bipolar Coagulation Electrosurgical Unit ...
March 2016 | $3600 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research